Psychedelic drug developer Compass Pathways is preparing to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression (TRD), after reporting positive ...
ATLANTA — Even at this late stage, nearly two-thirds through the schedule, answers have remained in limited supply for the Miami Heat when it comes to depth for success. In the power rotation, the ...
It's well known that many animals, including migratory birds, butterflies, and even fish, use the sun for navigational ...
Hosted on MSN
Compass Point downgrades Tanger (SKT)
Fintel reports that on February 26, 2026, Compass Point downgraded their outlook for Tanger (NYSE:SKT) from Buy to Neutral. Analyst Price Forecast Suggests 0.17% Downside As of February 25, 2026, the ...
Investing.com - Compass Point initiated coverage on BitGo Holdings (NYSE:BTGO) with a Buy rating and set a price target of $17.00, according to a research note published Monday. This target represents ...
Compass Point is adopting a bullish stance on Nebius Group . The firm initiated the artificial intelligence infrastructure stock with a buy rating and price target of $150, implying upside of 54%.
Upstart Holdings Inc. (NASDAQ:UPST) is one of the best growth stocks to buy for the next 20 years. On February 17, following the company’s Q4 2025 earnings report, Compass Point analyst Giuliano ...
Investing.com - Compass Point raised its price target on Terawulf Inc. (NASDAQ:WULF) to $28 from $17 while maintaining a Buy rating on the stock. The stock currently trades at $17.88, near its 52-week ...
When the score got out of hand, coach Kim Mulkey started experimenting. She played four guards. Then she played five. She even defied her nature and threw out a zone defense — something she hardly ...
The U.S.-China relationship affects national security and our pocketbooks. They are the world’s most advanced militaries and largest economies. Now, China’s increasingly authoritarian leadership is ...
— Finding Hope for FRRS1L plans to initiate clinical trial using TfR1 CapX gene therapy in the second half of 2026, pending regulatory review — FORT COLLINS, Colo. and NEW YORK, Feb. 18, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results